Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

PURPOSE: Metformin, widely used as antidiabetic drug, showed antitumoral effects expecially in combination with chemotherapy. Our group recently has demonstrated that metformin and gefitinib are synergistic in LKB1-wild-type NSCLC cells. In these models, metformin as single agent induced an activati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Della Corte, Carminia Maria, Ciaramella, Vincenza, Mauro, Concetta Di, Castellone, Maria Domenica, Papaccio, Federica, Fasano, Morena, Sasso, Ferdinando Carlo, Martinelli, Erika, Troiani, Teresa, De Vita, Ferdinando, Orditura, Michele, Bianco, Roberto, Ciardiello, Fortunato, Morgillo, Floriana
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2015
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826204/
https://ncbi.nlm.nih.gov/pubmed/26673006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6559
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia